{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:06:12Z","timestamp":1787501172369,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010573","name":"Stichting Dioraphte","doi-asserted-by":"publisher","award":["20010407"],"award-info":[{"award-number":["20010407"]}],"id":[{"id":"10.13039\/501100010573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["2020T065"],"award-info":[{"award-number":["2020T065"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Community","award":["101070917"],"award-info":[{"award-number":["101070917"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) have emerged as biomarkers for cerebral small vessel disease (SVD). We investigated their role in a hereditary SVD model, retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>NfL and GFAP levels of 17 pre-symptomatic, 22 symptomatic RVCL-S mutation carriers and 69 controls were measured using a Simoa assay. We assessed the association of serum and cerebrospinal fluid (CSF) levels of NfL and GFAP with RVCL-S symptomatology and neuropsychological functioning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Serum and CSF NfL levels were higher in symptomatic RVCL-S compared to controls\u2009\u2265\u200945\u00a0years (33.5\u00a0pg\/mL vs. 9.2\u00a0pg\/mL, p\u2009&lt;\u20090.01; 8.5*10\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0pg\/mL vs. 3.9*10\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0pg\/mL, p\u2009&lt;\u20090.01, respectively). Serum NfL levels were higher in symptomatic RVCL-S than pre-symptomatic carriers (33.5\u00a0pg\/mL vs. 5.9\u00a0pg\/mL, p\u2009=\u20090.02). Pre-symptomatic RVCL-S carriers had increased CSF NfL levels compared to controls\u2009&lt;\u200945\u00a0years (5.2*10\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0pg\/mL vs. 1.9*10\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0pg\/mL, p\u2009&lt;\u20090.01). No differences were found in GFAP levels across groups, but in RVCL-S carriers higher serum levels of both NfL and GFAP were linked to poorer global cognitive functioning (\u03b2[95%CI]\u2009=\u2009\u2212\u00a02.86 [\u2212\u00a05.58 to \u2212\u00a00.13], p\u2009=\u20090.04 and \u03b2[95%CI]\u2009=\u2009 \u2212\u00a06.85 [\u2212\u00a011.54 to \u2212\u00a02.15], p\u2009=\u20090.01, respectively) and prolonged psychomotor test times (\u03b2[95%CI]\u2009=\u20096.71 [0.78\u201312.65], p\u2009=\u20090.03 and \u03b2[95%CI]\u2009=\u200913.84 [3.09\u201324.60], p\u2009=\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Higher levels of serum NfL and GFAP are associated with worse cognitive functioning in RVCL-S carriers and may serve as marker for disease progression. CSF NfL levels may serve as early marker as pre-symptomatic RVCL-S patients already show differences compared to young controls.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-024-12292-6","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T03:02:05Z","timestamp":1712372525000},"page":"4138-4145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["NFL and GFAP in (pre)symptomatic RVCL-S carriers: a monogenic cerebral small vessel disease"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1789-1140","authenticated-orcid":false,"given":"Annelise E.","family":"Wilms","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. G. J. G.","family":"in\u2019t Veld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. A. M.","family":"Middelkoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. M.","family":"Terwindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,6]]},"reference":[{"key":"12292_CR1","volume":"3","author":"AE Wilms","year":"2022","unstructured":"Wilms AE, de Boer I, Terwindt GM (2022) Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S): an update on basic science and clinical perspectives. Cereb Circ Cogn Behav 3:100046","journal-title":"Cereb Circ Cogn Behav"},{"issue":"9","key":"12292_CR2","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/ng2082","volume":"39","author":"A Richards","year":"2007","unstructured":"Richards A et al (2007) C-terminal truncations in human 3\u2019-5\u2019 DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet 39(9):1068\u20131070","journal-title":"Nat Genet"},{"issue":"2","key":"12292_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/brain\/121.2.303","volume":"121","author":"GM Terwindt","year":"1998","unstructured":"Terwindt GM et al (1998) Clinical and genetic analysis of a large Dutch family with autosomal dominant vascular retinopathy, migraine and Raynaud\u2019s phenomenon. Brain 121(2):303\u2013316","journal-title":"Brain"},{"issue":"9","key":"12292_CR4","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3174\/ajnr.A7194","volume":"42","author":"ES Hoogeveen","year":"2021","unstructured":"Hoogeveen ES et al (2021) Neuroimaging findings in retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. AJNR Am J Neuroradiol 42(9):1604\u20131609","journal-title":"AJNR Am J Neuroradiol"},{"issue":"11","key":"12292_CR5","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1093\/brain\/aww217","volume":"139","author":"AH Stam","year":"2016","unstructured":"Stam AH et al (2016) Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. Brain 139(11):2909\u20132922","journal-title":"Brain"},{"issue":"3","key":"12292_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/joim.12848","volume":"285","author":"N Pelzer","year":"2019","unstructured":"Pelzer N et al (2019) Systemic features of retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations: a monogenic small vessel disease. J Intern Med 285(3):317\u2013332","journal-title":"J Intern Med"},{"issue":"10","key":"12292_CR7","doi-asserted-by":"crossref","first-page":"e956","DOI":"10.1212\/WNL.0000000000006119","volume":"91","author":"I de Boer","year":"2018","unstructured":"de Boer I et al (2018) RVCL-S and CADASIL display distinct impaired vascular function. Neurology 91(10):e956\u2013e963","journal-title":"Neurology"},{"issue":"12","key":"12292_CR8","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1161\/STROKEAHA.117.018556","volume":"48","author":"N Pelzer","year":"2017","unstructured":"Pelzer N et al (2017) Circulating endothelial markers in retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. Stroke 48(12):3301\u20133307","journal-title":"Stroke"},{"issue":"4","key":"12292_CR9","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1177\/0271678X20929430","volume":"41","author":"ES Hoogeveen","year":"2021","unstructured":"Hoogeveen ES et al (2021) Cerebrovascular reactivity in retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. J Cereb Blood Flow Metab 41(4):831\u2013840","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"12292_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE et al (2022) Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol 21(1):66\u201377","journal-title":"Lancet Neurol"},{"issue":"11","key":"12292_CR11","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1002\/acn3.51188","volume":"7","author":"WJC van Ballegoij","year":"2020","unstructured":"van Ballegoij WJC et al (2020) Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy. Ann Clin Transl Neurol 7(11):2127\u20132136","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"12292_CR12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s11910-022-01227-1","volume":"22","author":"M Kaisey","year":"2022","unstructured":"Kaisey M et al (2022) An update on diagnostic laboratory biomarkers for multiple sclerosis. Curr Neurol Neurosci Rep 22(10):675\u2013688","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"10","key":"12292_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14(10):577\u2013589","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"12292_CR14","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L et al (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90(8):870\u2013881","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"12292_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/acn3.678","volume":"6","author":"G Gravesteijn","year":"2019","unstructured":"Gravesteijn G et al (2019) Serum neurofilament light correlates with CADASIL disease severity and survival. Ann Clin Transl Neurol 6(1):46\u201356","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"12292_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.5853\/jos.2017.02565","volume":"20","author":"M Duering","year":"2018","unstructured":"Duering M et al (2018) Serum neurofilament light chain levels are related to small vessel disease burden. J Stroke 20(2):228\u2013238","journal-title":"J Stroke"},{"issue":"2","key":"12292_CR17","doi-asserted-by":"publisher","first-page":"296","DOI":"10.5853\/jos.2021.04385","volume":"24","author":"MA Jacob","year":"2022","unstructured":"Jacob MA et al (2022) Increased neurofilament light chain is associated with increased risk of long-term mortality in cerebral small vessel disease. J Stroke 24(2):296\u2013299","journal-title":"J Stroke"},{"issue":"6","key":"12292_CR18","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","volume":"38","author":"Z Yang","year":"2015","unstructured":"Yang Z, Wang KKW (2015) Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci 38(6):364\u2013374","journal-title":"Trends Neurosci"},{"issue":"6","key":"12292_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/jnnp-2021-328547","volume":"93","author":"P Oeckl","year":"2022","unstructured":"Oeckl P et al (2022) Serum GFAP differentiates Alzheimer\u2019s disease from frontotemporal dementia and predicts MCI-to-dementia conversion. J Neurol Neurosurg Psychiatry 93(6):659\u2013667","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"12292_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3233\/JAD-180325","volume":"67","author":"P Oeckl","year":"2019","unstructured":"Oeckl P et al (2019) Glial fibrillary acidic protein in serum is increased in Alzheimer\u2019s disease and correlates with cognitive impairment. J Alzheimers Dis 67(2):481\u2013488","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"12292_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","volume":"18","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak A et al (2022) Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol 18(3):158\u2013172","journal-title":"Nat Rev Neurol"},{"key":"12292_CR22","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1192\/bjp.149.6.698","volume":"149","author":"M Roth","year":"1986","unstructured":"Roth M et al (1986) CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149:698\u2013709","journal-title":"Br J Psychiatry"},{"issue":"5","key":"12292_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1037\/h0044509","volume":"19","author":"RM Reitan","year":"1955","unstructured":"Reitan RM (1955) The relation of the trail making test to organic brain damage. J Consult Psychol 19(5):393\u2013394","journal-title":"J Consult Psychol"},{"issue":"3","key":"12292_CR24","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1017\/S1355617709090626","volume":"15","author":"I S\u00e1nchez-Cubillo","year":"2009","unstructured":"S\u00e1nchez-Cubillo I et al (2009) Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition\/interference control, and visuomotor abilities. J Int Neuropsychol Soc 15(3):438\u2013450","journal-title":"J Int Neuropsychol Soc"},{"issue":"5","key":"12292_CR25","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","volume":"19","author":"JC van Swieten","year":"1988","unstructured":"van Swieten JC et al (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19(5):604\u2013607","journal-title":"Stroke"},{"key":"12292_CR26","first-page":"61","volume":"14","author":"FI Mahoney","year":"1965","unstructured":"Mahoney FI, Barthel DW (1965) Functional evaluation: the Barthel index. Md State Med J 14:61\u201365","journal-title":"Md State Med J"},{"issue":"10","key":"12292_CR27","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","volume":"54","author":"J Kuhle","year":"2016","unstructured":"Kuhle J et al (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 54(10):1655\u20131661","journal-title":"Clin Chem Lab Med"},{"issue":"7","key":"12292_CR28","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1093\/brain\/awaa098","volume":"143","author":"AR Gafson","year":"2020","unstructured":"Gafson AR et al (2020) Neurofilaments: neurobiological foundations for biomarker applications. Brain 143(7):1975\u20131998","journal-title":"Brain"},{"issue":"4","key":"12292_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/nan.12338","volume":"43","author":"CJ Garwood","year":"2017","unstructured":"Garwood CJ et al (2017) Review: astrocytes in Alzheimer\u2019s disease and other age-associated dementias: a supporting player with a central role. Neuropathol Appl Neurobiol 43(4):281\u2013298","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"8","key":"12292_CR30","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3390\/biomedicines10081869","volume":"10","author":"A Huss","year":"2022","unstructured":"Huss A et al (2022) Association of serum GFAP with functional and neurocognitive outcome in sporadic small vessel disease. Biomedicines 10(8):1869","journal-title":"Biomedicines"},{"issue":"20","key":"12292_CR31","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1212\/WNL.0000000000004645","volume":"89","author":"T Gattringer","year":"2017","unstructured":"Gattringer T et al (2017) Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology 89(20):2108\u20132114","journal-title":"Neurology"},{"issue":"2","key":"12292_CR32","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/S2666-7568(20)30061-1","volume":"2","author":"IMW Verberk","year":"2021","unstructured":"Verberk IMW et al (2021) Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Lancet Healthy Longev 2(2):e87\u2013e95","journal-title":"Lancet Healthy Longev"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12292-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12292-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12292-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T06:25:51Z","timestamp":1720506351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12292-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,6]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["12292"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12292-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,6]]},"assertion":[{"value":"10 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AEW, NP, SGJGV and HAMM have no disclosures. IB reports independent research support from the Dutch Heart Foundation (2020T065). GMT reports grants or consultancy support from Novartis, Lilly, Teva, Allergan, and independent support from Netherlands Organization for Health Research and Development (NWO, and ZonMW), NIH, European Community (101070917), Dutch Heart Foundation, Dutch Brain Foundation, IRRF, Stichting Dioraphte (20010407), and the Clayco foundation. CET reports grants or contracts for Research of the European Commission (Marie Curie International Training Network, 860197), Innovative Medicines Initiatives 3TR (Horizon 2020, 831434), EPND (IMI 2 Joint Undertaking (JU), 101034344) and JPND (bPRIDE), National MS Society, Alzheimer Drug Discovery Foundation, Alzheimer Association, Health Holland, the Dutch Research Council (ZonMW, including TAP-dementia (10510032120003)), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, ABOARD (a public\u2013private partnership receiving funding from ZonMW (#73305095007) and Health\u2009~\u2009Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). CET is also a contract researcher for ADx Neurosciences, AC-Immune, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly Fujirebio, Grifols, Instant Nano Biosensors, Merck, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Siemens, Toyama, Vivoryon, and the European Commission, and has received payment or honoraria from Roche, Novo Nordisk, and Grifols, where all payments were made to her institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}